Legend Biotech shares rise over 40 percent after early in vivo CAR-T data
Legend Biotech shares rose more than 40 percent after the company released early clinical data for its in vivo CAR-T therapy targeting Non-Hodgkin’s lymphoma. The stock moved higher while most other biotech shares declined.
insidermonkey.comLegend Biotech shares rose more than 40 percent after the company released early clinical data for its in vivo CAR-T therapy targeting Non-Hodgkin’s lymphoma. The data were disclosed on June 2, 2026. The company said the therapy showed promise in patients with the blood cancer.
Biotech stocks fell broadly on the same day.
Legend Biotech was one of the few companies whose shares moved higher. The stock reaction followed the release of the early-stage results. No additional details on trial size or duration were provided in the initial disclosure.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
ForbesNASA Retires MAVEN After 11 Years of Mars Atmosphere Discoveries Following Unrecoverable Anomaly
The agency confirmed Wednesday that the orbiter, launched in 2013, is beyond recovery following a fast spin that drained its batteries. MAVEN completed more than a decade of atmospheric observations at Mars.
foxnews.comTrump Budget Reduces CDC Wastewater Surveillance Funding From $125M to $25M Annually
President Donald Trump's budget plan reduces annual funding for the CDC's National Wastewater Surveillance System from $125 million to $25 million, limiting national coverage after September 30, 2026.